Summary
48 / 100 · Bulios Score
What speaks for it
- Revenue grew by 27% a year over the last 3 years.
- It holds more cash than debt: $484.9M against $435.0M.
- Analysts expect revenue to grow by 52% this fiscal year.
- It earns 14 USD a year on every 100 USD of invested capital.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Operating profit covers the interest on its debt only 1.1 times.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 58% a year over 5 years. Over the last 3 years it grew by 27% a year. For the next fiscal year analysts expect revenue to grow by 52%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $9.33M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $39 is 22% above today's price. 64% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Sale of Therapies 100%
By region
- UNITED STATES 64%
- Europe 33%
- Rest of World 2.9%
Sale of Therapies brings in 100% of revenue.
Segments in detail